Allogene Therapeutics (ALLO) Long-Term Investments (2019 - 2025)
Historic Long-Term Investments for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $24.9 million.
- Allogene Therapeutics' Long-Term Investments fell 7769.29% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 7769.29%. This contributed to the annual value of $80.7 million for FY2024, which is 211325.1% up from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Long-Term Investments is $24.9 million, which was down 7769.29% from $29.5 million recorded in Q2 2025.
- Allogene Therapeutics' Long-Term Investments' 5-year high stood at $378.2 million during Q3 2021, with a 5-year trough of $1.1 million in Q2 2024.
- For the 5-year period, Allogene Therapeutics' Long-Term Investments averaged around $125.9 million, with its median value being $59.2 million (2022).
- In the last 5 years, Allogene Therapeutics' Long-Term Investments tumbled by 9784.35% in 2024 and then soared by 250229.28% in 2025.
- Quarter analysis of 5 years shows Allogene Therapeutics' Long-Term Investments stood at $352.2 million in 2021, then tumbled by 83.2% to $59.2 million in 2022, then plummeted by 93.84% to $3.6 million in 2023, then surged by 2113.25% to $80.7 million in 2024, then plummeted by 69.08% to $24.9 million in 2025.
- Its Long-Term Investments was $24.9 million in Q3 2025, compared to $29.5 million in Q2 2025 and $55.5 million in Q1 2025.